JP2018531892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531892A5 JP2018531892A5 JP2018507527A JP2018507527A JP2018531892A5 JP 2018531892 A5 JP2018531892 A5 JP 2018531892A5 JP 2018507527 A JP2018507527 A JP 2018507527A JP 2018507527 A JP2018507527 A JP 2018507527A JP 2018531892 A5 JP2018531892 A5 JP 2018531892A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pde3a
- subject
- cell
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021114249A JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204875P | 2015-08-13 | 2015-08-13 | |
| US62/204,875 | 2015-08-13 | ||
| PCT/US2016/046912 WO2017027854A1 (en) | 2015-08-13 | 2016-08-12 | Compositions and methods for cancer expressing pde3a or slfn12 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114249A Division JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531892A JP2018531892A (ja) | 2018-11-01 |
| JP2018531892A5 true JP2018531892A5 (cg-RX-API-DMAC7.html) | 2019-09-26 |
| JP6968054B2 JP6968054B2 (ja) | 2021-11-17 |
Family
ID=57983814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507527A Active JP6968054B2 (ja) | 2015-08-13 | 2016-08-12 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
| JP2021114249A Pending JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021114249A Pending JP2021169488A (ja) | 2015-08-13 | 2021-07-09 | Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11207320B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3334404B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6968054B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114699528A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2995375C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017027854A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107529A1 (es) | 2016-02-05 | 2018-05-09 | Bayer Pharma AG | Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento |
| CN107312824A (zh) * | 2016-04-26 | 2017-11-03 | 中国科学院上海药物研究所 | Pde3a在判断阿那格雷治疗肿瘤效果中的应用 |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| US11897867B2 (en) | 2017-08-04 | 2024-02-13 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer |
| TW202031677A (zh) * | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Ｐｄｅ３調節劑反應性癌症之鑑定 |
| AR117929A1 (es) | 2019-02-01 | 2021-09-01 | Bayer Ag | Compuestos de 1,2,4-triazin-3(2h)-ona |
| CN112402613A (zh) * | 2019-08-23 | 2021-02-26 | 中国科学院上海药物研究所 | Pde3抑制剂与细胞因子联合治疗肿瘤的应用 |
| CA3212314A1 (en) * | 2021-03-03 | 2022-09-09 | Bayer Aktiengesellschaft | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma |
| WO2022199627A1 (en) * | 2021-03-23 | 2022-09-29 | National Institute Of Biological Sciences, Beijing | Polycyclic compounds and uses thereof |
| CN114814221A (zh) * | 2022-02-24 | 2022-07-29 | 中南大学湘雅医院 | 一种甲状腺癌早期诊断标志物及其应用 |
| CN116705196B (zh) * | 2023-06-28 | 2025-08-19 | 湖南师范大学 | 基于符号图神经网络的药物靶标互作用预测方法及装置 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4092311A (en) | 1976-06-03 | 1978-05-30 | American Cyanamid Company | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates |
| JPS6061570A (ja) | 1983-09-16 | 1985-04-09 | Sankyo Co Ltd | ピリダジノン誘導体及び農業用殺菌剤 |
| US5053338A (en) | 1989-09-01 | 1991-10-01 | Glaxo Inc. | Kinetic resolution of pyridazinones using lipase |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| JPH05140116A (ja) | 1991-11-21 | 1993-06-08 | Nippon Soda Co Ltd | 光学活性な化合物 |
| EP0791584A4 (en) | 1994-11-11 | 1997-11-19 | Nippon Soda Co | OPTICALLY ACTIVE CONNECTIONS |
| EP1406621A2 (en) * | 2001-06-26 | 2004-04-14 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
| CN101537006B (zh) | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 |
| CN102858999A (zh) * | 2009-12-01 | 2013-01-02 | 简要生物科学有限公司 | 癌症的分类 |
| CN105039520A (zh) * | 2011-08-03 | 2015-11-11 | 西格诺药品有限公司 | 作为lkb1状态的预测性生物标志物的基因表达谱的鉴定 |
| JP6511430B2 (ja) | 2013-03-11 | 2019-05-15 | ザ・ブロード・インスティテュート・インコーポレイテッド | がんの治療のための化合物および組成物 |
| AU2014336016B2 (en) * | 2013-10-17 | 2019-12-19 | Sartar Therapeutics Ltd | Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient |
| JP5852759B1 (ja) * | 2015-04-01 | 2016-02-03 | 株式会社キュービクス | 遺伝子発現解析による膵臓癌の検出 |
| AR107529A1 (es) | 2016-02-05 | 2018-05-09 | Bayer Pharma AG | Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento |
| EP3576742B1 (en) * | 2017-02-03 | 2025-07-02 | The Broad Institute, Inc. | 6-[3,5-dihalogeno-4-(morpholin-4-yl)phenyl]-5-methyl-4,5-dihydropyridazin-3(2h)-one, modulators of pde3a or 3b for use in the treatment of cancer |
| TW202031677A (zh) * | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Ｐｄｅ３調節劑反應性癌症之鑑定 |
-
2016
- 2016-08-12 WO PCT/US2016/046912 patent/WO2017027854A1/en not_active Ceased
- 2016-08-12 CA CA2995375A patent/CA2995375C/en active Active
- 2016-08-12 EP EP16836014.7A patent/EP3334404B1/en active Active
- 2016-08-12 CN CN202210036941.5A patent/CN114699528A/zh active Pending
- 2016-08-12 JP JP2018507527A patent/JP6968054B2/ja active Active
- 2016-08-12 US US15/752,130 patent/US11207320B2/en active Active
- 2016-08-12 CN CN201680059256.7A patent/CN108366947B/zh active Active
-
2021
- 2021-07-09 JP JP2021114249A patent/JP2021169488A/ja active Pending
- 2021-11-18 US US17/530,402 patent/US20220071995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531892A5 (cg-RX-API-DMAC7.html) | ||
| Nault et al. | Biomarkers for hepatobiliary cancers | |
| Schütte et al. | Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma | |
| Gobin et al. | Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models | |
| Kim et al. | Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin | |
| Liu et al. | ER stress‐related ATF 6 upregulates CIP 2A and contributes to poor prognosis of colon cancer | |
| Paysan et al. | Rnd3 in cancer: a review of the evidence for tumor promoter or suppressor | |
| Alberobello et al. | PI3K as a potential therapeutic target in thymic epithelial tumors | |
| Trigka et al. | A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features | |
| CY1122647T1 (el) | Μεθοδος ανιχνευσης των pik3ca μεταλλαξεων σε ενα δειγμα | |
| Ingels et al. | Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts | |
| Duan et al. | Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine | |
| MX2013004305A (es) | Metodos para determinar isotipos de anticuerpos anti-farmacos. | |
| CA2835179A1 (en) | Markers for cancer prognosis and therapy and methods of use | |
| Losert et al. | The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells | |
| MX2022012384A (es) | Composiciones y metodos para cribar mutaciones en el cancer de tiroides. | |
| EP4435112A3 (en) | Compositions and methods for screening solid tumors | |
| Zhao et al. | Ubiquitin D is an independent prognostic marker for survival in stage IIB–IIC colon cancer patients treated with 5‐fluoruracil‐based adjuvant chemotherapy | |
| WO2007085497A3 (en) | Markers for the prediction of outcome of anthracycline treatment | |
| JP2009537798A5 (cg-RX-API-DMAC7.html) | ||
| Tran et al. | Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management | |
| Gao et al. | C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients | |
| Seiwert | Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing | |
| Tsai et al. | A clustered ground‐glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery | |
| Van Dam et al. | Potential new biomarkers for squamous carcinoma of the uterine cervix |